Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidation

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 287, Issue 4 56-4, 2004, Pages

  Chandler, Margaret P ^a   Kerner, Janos ^b   Huang, Hazel ^a   Vazquez, Edwin ^c   Reszko, Aneta ^b   Martini, Wenjun Z ^a,b   Hoppel, Charles L ^a,c   Imai, Makoto ^d   Rastogi, Sharad ^d   Sabbah, Hani N ^d   Stanley, William C ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c Research Service   (United States)

^d HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

Cardiac; Malonyl CoA; Metabolism

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARBON 13; CARBON 14; CARNITINE PALMITOYLTRANSFERASE; CITRIC ACID; FATTY ACID; FUMARIC ACID; GLUCOSE; GLYCOGEN; LACTIC ACID; MALONYL COENZYME A; OLEIC ACID; PYRUVATE DEHYDROGENASE; SUCCINIC ACID; TRITIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CITRIC ACID CYCLE; CONTROLLED STUDY; DOG; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID OXIDATION; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; HEART FAILURE; HEART HEMODYNAMICS; IN VIVO STUDY; MICHAELIS CONSTANT; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BLOOD GLUCOSE; CARNITINE O-PALMITOYLTRANSFERASE; DOGS; DOWN-REGULATION; FATTY ACIDS, NONESTERIFIED; HEART FAILURE, CONGESTIVE; HEART RATE; LACTIC ACID; MALONYL COENZYME A; MYOCARDIUM; OLEIC ACID; OXIDATION-REDUCTION; PYRUVATE DEHYDROGENASE COMPLEX; SEVERITY OF ILLNESS INDEX; VENTRICULAR PRESSURE;

EID: 4744373271     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00281.2004     Document Type: Article

References (47)

1. Andersson B, Blomstrom-Lundqvist C, Hedner T, and Waagstein F. Exercise hemodynamics and myocardial metabolism during long-term beta-adrenergic blockade in severe heart failure. J Am Coll Cardiol 18: 1059-1066, 1991.
2. Bersin RM, Wolfe C, Kwasman M, Lau D, Klinski C, Tanaka K, Khorrami P, Henderson GN, de Marco T, and Chatterjee K. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 23: 1617-1624, 1994.
3. Chandler MP, Huang H, McElfresh TA, and Stanley WC. Increased nonoxidative glycolysis despite continued fatty acid uptake during demand-induced myocardial ischemia. Am J Physiol Heart Circ Physiol 282: H1871-H1878, 2002.
4. Chandler MP, Stanley WC, Morita H, Suzuki G, Roth BA, Blackburn B, Wolff A, and Sabbah HN. Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ Res 91: 278-280, 2002.
5. Christe ME and Rodgers RL. Altered glucose and fatty acid oxidation in hearts of the spontaneously hypertensive rat. J Mol Cell Cardiol 26: 1371-1375, 1994.
6. Comte B, Vincent G, Bouchard B, and des Rosiers C. Probing the origin of acetyl-CoA and oxaloacetate entering the citric acid cycle from the 13C labeling of citrate released by perfused rat hearts. J Biol Chem 272: 26117-26124, 1997.
7. Davila-Roman VG, Vedala G, Herrero P, de las FL, Rogers JG, Kelly DP, and Gropler RJ. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardlol 40: 271-277, 2002.
8. 2+ in hearts of cardiomyopathic hamsters. Am J Physiol Heart Circ Physiol 264: H2188-H2197, 1993.
9. Dyck JR and Lopaschuk GD. Malonyl CoA control of fatty acid oxidation in the ischemic heart. J Mol Cell Cardiol 34: 1099-1109, 2002.
10. Fannin SW, Lesnefsky EJ, Slabe TJ, Hassan MO, and Hoppel CL. Aging selectively decreases oxidative capacity in rat heart interfibrillar mitochondria. Arch Biochem Biophys 372: 399-407, 1999.
11. Fraser F, Corstorphine CG, and Zammit VA. Topology of carnitine palmitoyltransferase I in the mitochondrial outer membrane. Biochem J 323: 711-718, 1997.
12. From AH. Should manipulation of myocardial substrate utilization patterns be a component of the congestive heart failure therapeutic paradigm? J Card Fail 4: 127-129, 1998.
13. Hall JL, Van Wylen DG, Pizzurro RD, Hamilton CD, Reiling CM, and Stanley WC. Myocardial interstitial purine metabolites and lactate with increased work in swine. Cardiovasc Res 30: 351-356, 1995.
14. Hermann HP, Pieske B, Schwarzmuller E, Keul J, Just H, and Hasenfuss G. Haemodynamic effects of intracoronary pyruvate in patients with congestive heart failure: an open study. Lancet 353: 1321-1323, 1999.
15. Hoppel CL, Kerner J, Turkaly P, Turkaly J, and Tandler B. The malonyl-CoA-sensitive form of carnitine palmitoyltransferase is not localized exclusively in the outer membrane of rat liver mitochondria. J Biol Chem 273: 23495-23503, 1998.
16. Iemitsu M, Miyauchi T, Maeda S, Tanabe T, Takanashi M, Irukayama-Tomobe Y, Sakai S, Ohmori H, Matsuda M, and Yamaguchi I. Aging-induced decrease in the PPAR-α level in hearts is improved by exercise training. Am J Physiol Heart Circ Physiol 283: H1750-H1760, 2002.
17. Kerner J and Hoppel C. Fatty acid import into mitochondria. Biochim Biophys Acta 1486: 1-17, 2000.
18. Kerner J and Hoppel CL. Radiochemical malonyl-CoA decarboxylase assay: activity and subcellular distribution in heart and skeletal muscle. Anal Biochem 306: 283-289, 2002.
19. Kerner J, Zaluzec E, Gage D, and Bieber LL. Characterization of the malonyl-CoA-sensitive carnitine palmitoyltransferase (CPTo) of a rat heart mitochondrial particle. Evidence that the catalytic unit is CPTi. J Biol Chem 269: 8209-8219, 1994.
20. Kudo N, Barr AJ, Barr RL, Desai S, and Lopaschuk GD. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 270: 17513-17520, 1995.
21. Lei B, Lionetti V, Young ME, Chandler MP, d'Agostino C, Kang E, Altarejos M, Matsuo K, Hintze TH, Stanley WC, and Recchia FA. Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure. J Mol Cell Cardiol 36: 567-576, 2004.
22. Massie BM, Schaefer S, Garcia J, McKirnan MD, Schwartz GG, Wisneski JA, Weiner MW, and White FC. Myocardial high-energy phosphate and substrate metabolism in swine with moderate left ventricular hypertrophy. Circulation 91: 1814-1823, 1995.
23. Mazer CD, Cason BA, Stanley WC, Shnier CB, Wisneski JA, and Hickey RF. Dichloroacetate stimulates carbohydrate metabolism but does not improve systolic function in ischemic pig heart. Am J Physiol Heart Circ Physiol 268: H879-H885, 1995.
24. McGarry JD and Brown NF. The mitochondrial carnitine palmitoyl- transferase system. From concept to molecular analysis. Eur J Biochem 244: 1-14, 1997.
25. Moghaddas S, Stoll MS, Minkler PE, Salomon RG, Hoppel CL, and Lesnefsky EJ. Preservation of cardiolipin content during aging in rat heart interfibrillar mitochondria. J Gerontol A Biol Sci Med Sci 57: B22-B28, 2002.
26. Osorio JC, Stanley WC, Linke A, Castellari M, Diep QN, Panchal AR, Hintze TH, Lopaschuk GD, and Recchia FA. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation 106: 606-612, 2002.
27. Palmer JW, Tandler B, and Hoppel CL. Biochemical properties of subsarcolemmal and interfibrillar mitochondria isolated from rat cardiac muscle. J Biol Chem 252: 8731-8739, 1977.
28. Panchal AR, Comte B, Huang H, Kerwin T, Darvish A, des RC, Brunengraber H, and Stanley WC. Partitioning of pyruvate between oxidation and anaplerosis in swine hearts. Am J Physiol Heart Circ Physiol 279: H2390-H2398, 2000.
29. Panchal AR, Stanley WC, Kerner J, and Sabbah HN. Beta-receptor blockade decreases carnitine palmitoyl transferase I activity in dogs with heart failure. J Card Fail 4: 121-126, 1998.
30. Paolisso G, Gambardella A, Galzerano D, D'Amore A, Rubino P, Verza M, Teasuro P, Varricchio M, and D'Onofrio F. Total-body and myocardial substrate oxidation in congestive heart failure. Metabolism 43: 174-179, 1994.
31. Passoneau JV and Lauderdale VR. A comparison of three methods of glycogen measurement in tissues. Anal Biochem 60: 405-412, 1974.
32. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, and Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation 104: 2923-2931, 2001.
33. Recchia FA, McConnell PI, Bernstein RD, Vogel TR, Xu X, and Hintze TH. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ Res 83: 969-979, 1998.
34. 13C-isotopic enrichment of malonyl-coenzyme A by gas chromatography-mass spectrometry. Anal Biochem 298: 69-75, 2001.
35. Sabbah HN, Chandler MP, Mishima T, Suzuki G, Chaudhry P, Nass O, Biesiadecki BJ, Blackburn B, Wolff A, and Stanley WC. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail 8: 416-422, 2002.
36. Sabbah HN, Shimoyama H, Kono T, Gupta RC, Sharov VG, Scicli G, Levine TB, and Goldstein S. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 89: 2852-2859, 1994.
37. Sabbah HN, Stanley WC, Sharov VG, Mishima T, Tanimura M, Benedict CR, Hegde S, and Goldstein S. Effects of dopamine β-hydroxylase inhibition with nepicastat on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Circulation 102: 1990-1995, 2000.
38. Sabbah HN, Stein PD, Kono T, Gheorghiade M, Levine TB, Jafri S, Hawkins ET, and Goldstein S. A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. Am J Physiol Heart Circ Physiol 260: H1379-H1384, 1991.
39. Sack MN, Rader TA, Park S, Bastin J, McCune SA, and Kelly DP. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 94: 2837-2842, 1996.
40. Sharov VG, Goussev A, Lesch M, Goldstein S, and Sabbah HN. Abnormal mitochondrial function in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol 30: 1757-1762, 1998.
41. Stanley WC and Chandler MP. Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Failure Reviews 7: 115-130, 2002.
42. Stanley WC, Hernandez LA, Spires D, Bringas J, Wallace S, and McCormack JG. Pyruvate dehydrogenase activity and malonyl CoA levels in normal and ischemic swine myocardium: effects of dichloroacetate. J Mol Cell Cardiol 28: 905-914, 1996.
43. Stanley WC and Hoppel CL. Mitochondrial dysfunction in heart failure: potential for therapeutic interventions? Cardiovasc Res 45: 805-806, 2000.
44. Stanley WC, Lopaschuk GD, Hall JL, and McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res 33: 243-257, 1997.
45. Sterk JP, Stanley WC, Hoppel CL, and Kerner J. A radiochemical pyruvate dehydrogenase assay: activity in heart. Anal Biochem 313: 179-182, 2003.
46. Taegtmeyer H and Overturf ML. Effects of moderate hypertension on cardiac function and metabolism in the rabbit. Hypertension 11: 416-426, 1988.
47. Wallhaus TR, Taylor M, DeGrado TR, Russell DC, Stanko P, Nickles RJ, and Stone CK. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 103: 2441-2446, 2001.